Aureus Asset Management Has Raised By $1.07 Million Its Macom Tech Solutions Hldgs Com (MTSI) Position; Atara Biotherapeutics (ATRA) Had 4 Bulls

June 20, 2017 - By Linda Rogers

Among 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 have Buy rating, 2 Sell and 0 Hold. Therefore 67% are positive. Atara Biotherapeutics had 13 analyst reports since September 9, 2015 according to SRatingsIntel. Citigroup downgraded the shares of ATRA in report on Tuesday, December 15 to “Sell” rating. The rating was maintained by JMP Securities with “Market Outperform” on Tuesday, December 15. Citigroup maintained the stock with “Sell” rating in Friday, August 19 report. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) has “Neutral” rating given on Wednesday, November 18 by Goldman Sachs. The stock has “Buy” rating by Canaccord Genuity on Wednesday, September 9. The company was reinitiated on Monday, October 24 by Jefferies. The rating was initiated by William Blair on Friday, October 9 with “Outperform”. The rating was downgraded by Goldman Sachs to “Sell” on Thursday, September 15. JMP Securities maintained it with “Market Outperform” rating and $34 target in Wednesday, March 9 report. Citigroup maintained it with “Sell” rating and $8 target in Monday, August 22 report. See Atara Biotherapeutics Inc (NASDAQ:ATRA) latest ratings:

Aureus Asset Management Llc increased Macom Tech Solutions Hldgs Inc Com (MTSI) stake by 9.42% reported in 2016Q4 SEC filing. Aureus Asset Management Llc acquired 23,340 shares as Macom Tech Solutions Hldgs Inc Com (MTSI)’s stock rose 15.15%. The Aureus Asset Management Llc holds 271,215 shares with $12.55M value, up from 247,875 last quarter. Macom Tech Solutions Hldgs Inc Com now has $3.83 billion valuation. The stock declined 0.61% or $0.35 reaching $57.71 on the news. About 219,681 shares traded. MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI) has risen 62.84% since June 20, 2016 and is uptrending. It has outperformed by 46.14% the S&P500.

Investors sentiment increased to 1.07 in Q4 2016. Its up 0.07, from 1 in 2016Q3. It improved, as 25 investors sold MTSI shares while 57 reduced holdings. 30 funds opened positions while 58 raised stakes. 40.64 million shares or 5.55% more from 38.50 million shares in 2016Q3 were reported. Neuberger Berman Ltd Liability Co has 1.05 million shares for 0.07% of their portfolio. Next Century Growth Invsts Ltd Liability Corp invested 0.79% in MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI). Dimensional Fund Advsrs Ltd Partnership reported 0.01% of its portfolio in MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI). Services Automobile Association holds 162,693 shares. Summit Partners LP invested in 1.22M shares. Loomis Sayles & Limited Partnership invested 0.01% in MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI). Paradigm Asset Mngmt reported 0% of its portfolio in MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI). Emerald Mutual Fund Advisers Tru holds 0.57% or 258,838 shares in its portfolio. Pnc Fincl Serv Grp holds 0% of its portfolio in MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI) for 56 shares. Eam Investors Limited Company reported 64,230 shares. Fernwood Invest Management Limited Liability Company reported 9,100 shares stake. Tiaa Cref Investment Mngmt Lc has invested 0% in MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI). Wellington Group Limited Liability Partnership holds 0.04% in MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI) or 3.48 million shares. Legal And General Public Limited Company has invested 0% in MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI). The Texas-based Segment Wealth Management Ltd Liability has invested 1.38% in MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI).

Since December 22, 2016, it had 0 insider purchases, and 32 selling transactions for $91.06 million activity. Dennehy Robert had sold 3,654 shares worth $165,380. The insider BLAND CHARLES R sold 750 shares worth $45,225. The insider Virk Preetinder S. sold 533 shares worth $32,401. Croteau John sold $96,858 worth of stock or 2,000 shares. VAN LUNSEN GIL J sold 1,000 shares worth $46,050. Another trade for 11,209 shares valued at $625,032 was sold by Behfar Alex. The insider OCAMPO JOHN L sold 59,750 shares worth $3.65 million.

Aureus Asset Management Llc decreased Apple Inc Com (NASDAQ:AAPL) stake by 4,124 shares to 92,562 valued at $10.72M in 2016Q4. It also reduced Booz Allen Hamilton Hldg Corp Cl A (NYSE:BAH) stake by 10,459 shares and now owns 429,765 shares. First Rep Bk San Francisco Cal Com (NYSE:FRC) was reduced too.

Among 8 analysts covering M/A-Com Technology Solutions Holdings (NASDAQ:MTSI), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. M/A-Com Technology Solutions Holdings had 19 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI) earned “Buy” rating by Stifel Nicolaus on Wednesday, January 27. The stock has “Buy” rating by Jefferies on Tuesday, August 18. On Tuesday, August 18 the stock rating was maintained by Needham with “Buy”. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, December 3. Goldman Sachs reinitiated MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI) on Wednesday, February 3 with “Buy” rating. Craig Hallum initiated the stock with “Buy” rating in Monday, January 11 report. The firm has “Buy” rating given on Wednesday, July 29 by Needham. The company was maintained on Wednesday, November 16 by Stifel Nicolaus. The firm has “Neutral” rating by Goldman Sachs given on Tuesday, September 20. Barclays Capital maintained the shares of MTSI in report on Friday, March 11 with “Overweight” rating.

Since December 22, 2016, it had 0 insider purchases, and 29 insider sales for $4.17 million activity. $596,808 worth of stock was sold by Ciechanover Isaac E. on Thursday, March 16. Haqq Christopher sold 6,000 shares worth $117,600. The insider Turner Heather D sold 12,215 shares worth $192,067. Soffer Gad had sold 6,274 shares worth $97,029. 1,183 shares were sold by Gallagher Carol Giltner, worth $19,046 on Wednesday, February 15. MCGRATH JOHN sold $136,260 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) on Tuesday, February 21. The insider Clark Mitchall G. sold 3,059 shares worth $48,822.

Investors sentiment increased to 1.86 in 2016 Q4. Its up 0.38, from 1.48 in 2016Q3. It increased, as 5 investors sold Atara Biotherapeutics Inc shares while 17 reduced holdings. 11 funds opened positions while 30 raised stakes. 22.89 million shares or 2.84% more from 22.25 million shares in 2016Q3 were reported. Alyeska Invest Grp Inc Lp stated it has 408,200 shares. Bnp Paribas Arbitrage Sa holds 1,302 shares. State Board Of Administration Of Florida Retirement Systems holds 10,253 shares. Morgan Stanley accumulated 70,689 shares or 0% of the stock. Deutsche Bancorp Ag holds 14,313 shares or 0% of its portfolio. Wells Fargo Mn reported 53,461 shares or 0% of all its holdings. Fmr Limited Liability Corporation invested in 0.01% or 2.78M shares. Bank & Trust Of America Corporation De stated it has 117,973 shares or 0% of all its holdings. Blackrock holds 11,615 shares. Great West Life Assurance Co Can owns 1,654 shares for 0% of their portfolio. Blackrock Group Inc holds 5,994 shares. Eagle Asset Management accumulated 1.11 million shares. Blackrock Investment Management Ltd Liability, New Jersey-based fund reported 92,922 shares. Moreover, Goldman Sachs Gp Inc has 0% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 28,030 shares. Tower Research Capital Lc (Trc) invested in 0% or 547 shares.

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $418.39 million. The Firm is focused on developing therapies for patients with severe and life-threatening diseases. It currently has negative earnings. The Firm operates through the business of developing and commercializing therapeutics segment.

About 104,487 shares traded. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 7.28% since June 20, 2016 and is downtrending. It has underperformed by 23.98% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: